Want to see IN:BIOCON full AI Analyst Report?

Biocon Limited (BIOCON) Price & Analysis

17 Followers

BIOCON Stock Chart & Stats

₹417.40

₹2.60(0.60%)

At close: Jul 27 4:00 PM EDT

₹417.40

₹2.60(0.60%)

Day’s Range― - ―

52-Week Range₹337.95 - ₹447.00

Previous CloseN/A

Volume2.57M

Average Volume (3M)714.80K

Market Cap

₹567.40B

Enterprise Value₹828.93B

Total Cash (Recent Filing)₹28.33B

Total Debt (Recent Filing)₹155.51B

Price to Earnings (P/E)102.8

Beta0.70

Next Earnings

Nov 05, 2026

EPS Estimate

0.97

Next Dividend Ex-DateN/A

Dividend Yield0.14%

Share Statistics

EPS (TTM)3.40

Shares Outstanding1,629,694,100

10 Day Avg. Volume165,651

30 Day Avg. Volume714,798

Financial Highlights & Ratios

PEG Ratio-1.92

Price to Book (P/B)1.45

Price to Sales (P/S)2.92

P/FCF Ratio-94.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)6.93

Revenue Forecast (FY)₹194.32B

Bulls Say, Bears Say

Bulls Say

Diversified Biopharma PlatformBiocon’s presence across biosimilars, generic formulations, and biologics-related services gives it multiple routes to commercialize scientific capabilities. This breadth can support more resilient growth over the next several quarters by balancing product launches, recurring medicines, and service-related revenue.

Multi-year Revenue GrowthStrong multi-year revenue expansion indicates that Biocon has continued to broaden its commercial base despite operating in regulated and competitive markets. Sustained top-line growth can provide the scale needed to support research, manufacturing investment, and future product commercialization.

Improved LeverageThe substantial reduction in debt-to-equity improves Biocon’s capital structure and lowers balance-sheet pressure compared with prior years. Greater leverage discipline should preserve financial flexibility for product development and expansion, while making the business better able to absorb earnings volatility.

Bears Say

Sharp Margin CompressionThe latest profitability reset materially weakens earnings quality, as both gross and net margins declined from prior-year levels. Unless margins recover, lower conversion of revenue into profit could constrain reinvestment, reduce operating resilience, and make future earnings more volatile.

Negative Free Cash FlowNegative free cash flow shows that recent earnings are not translating effectively into internally generated funds. Continued weak cash conversion could increase reliance on external financing or asset monetization, limiting flexibility to fund development, capacity, and commercial priorities.

Very Low Return On EquityAn ROE of roughly 1.1% indicates that Biocon is currently generating very limited profit from shareholder capital. This weak efficiency reflects the recent profitability pressure and may limit the company’s ability to compound equity value unless earnings and margins improve sustainably.

Biocon Limited News

Biocon’s Pertuzumab Biosimilar Wins Key EMA CHMP Backing Under New Regulatory Path

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Biologics, the biosimilars arm of Biocon Limited, has...

20d ago

Biocon Confirms Electronic Remittance of FY 2025-26 Final Dividend

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited has notified stock exchanges that it has...

1M ago

Biocon Wins 10-Year Brazil Supply Deal for Breast Cancer Drug Pertuzumab

Biocon Limited ( ($IN:BIOCON) ) has issued an announcement. Biocon Limited has secured a 10-year Productive Development Partnership...

1M ago

Biocon Completes Electronic Remittance of Final Dividend for FY 2025-26

An announcement from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has notified the BSE and...

1M ago

Biocon Wins Japan Approval for Pegfilgrastim Biosimilar, Expanding Biosimilars Footprint

Biocon Limited ( ($IN:BIOCON) ) just unveiled an announcement. Biocon Biologics, a subsidiary of Biocon Limited, has received...

2M ago

Biocon Shareholders Strongly Back 2026 Financials at 48th AGM

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Limited, a leading Indian biopharmaceutical company,...

2M ago

Biocon schedules Q1 FY27 earnings call and shares investor presentation

Biocon Limited ( ($IN:BIOCON) ) has shared an update. Biocon Limited has notified stock exchanges that it will...

2M ago

Biocon Wins Health Canada Approval for Yesintek Ustekinumab Autoinjector Pen

Biocon Limited ( ($IN:BIOCON) ) has issued an announcement. Biocon’s Canadian subsidiary has received Health Canada’s Notice of...

2M ago

Biocon makes Biocon Biologics a wholly owned unit via share swap

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has acquired 11,536,956 equity shares of its...

3M ago

Biocon Makes Biocon Biologics Wholly Owned Via Preferential Share Issue

An announcement from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has completed the acquisition of...

3M ago

BIOCON FAQ

What was Biocon Limited’s price range in the past 12 months?

Biocon Limited lowest stock price was ₹337.95 and its highest was ₹447.00 in the past 12 months.

What is Biocon Limited’s market cap?

Biocon Limited’s market cap is ₹567.40B.

When is Biocon Limited’s upcoming earnings report date?

Biocon Limited’s upcoming earnings report date is Nov 05, 2026 which is in 25 days.

How were Biocon Limited’s earnings last quarter?

Biocon Limited released its earnings results on Aug 05, 2026. The company reported ₹0.87 earnings per share for the quarter, missing the consensus estimate of ₹1.005 by -₹0.135.

Is Biocon Limited overvalued?

According to Wall Street analysts Biocon Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biocon Limited pay dividends?

Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.14%. See more information on Biocon Limited dividends here

What is Biocon Limited’s EPS estimate?

Biocon Limited’s EPS estimate is 0.97.

How many shares outstanding does Biocon Limited have?

Biocon Limited has 1,629,694,100 shares outstanding.

What happened to Biocon Limited’s price movement after its last earnings report?

Biocon Limited reported an EPS of ₹0.87 in its last earnings report, missing expectations of ₹1.005. Following the earnings report the stock price went down -0.035%.

Which hedge fund is a major shareholder of Biocon Limited?

Currently, no hedge funds are holding shares in IN:BIOCON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biocon Limited

Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.